Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Six Launches, Six Filings Slated For ’06: Sign Of R&D Strategy Payoff?

Executive Summary

GlaxoSmithKline plans to end 2006 with six product launches and six regulatory filings, CEO J.P. Garnier said during a presentation at the Bear Stearns Healthcare conference in New York Sept. 13
Advertisement

Related Content

GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO
Pfizer Should Expand Maraviroc Postmarketing Safety Plans – Cmte.
GSK extends CEO’s contract
GSK R&D chairman
GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements
Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18
Merck Initiates Gardasil Detailing; Campaign To Focus On Cancer Prevention
GSK Informs Canadian Wholesalers Of Coreg, Paxil, Relafen Shortages
Migraine Two-Hour Pain Response Efficacy Standard Suggested By Committee
Avandaryl Approval On Track Despite Consent Decree, GSK Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS046357

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel